Cancer and neoplasms

M25-288 Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Advanced or Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288 (AndroMETa-PDAC-288)

GO TO STUDY

Cancer and neoplasms

BDTX-4933-101 - A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

GO TO STUDY

Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, randomized, placebo-controlled, double-blind, crossover study

GO TO STUDY

Exploring the lived experience of patients with Congenital Myasthenic Syndromes (CMS) about assessment tools used clinically and patient view on what might capture meaningful change.

GO TO STUDY

Oral and Gastrointestinal

Trial to Evaluate Safety, Tolerability, PK, and Mechanism of Action of Zasocitinib in Participants With Moderately-to-Severely Active Crohn’s Disease (ZODIAC)

GO TO STUDY

Neurological

A Phase I, 2-Part Study to evaluate the safety, tolerability, pharmacokinets, and pharmacodynamics of single-ascending doses of intrathecally administered RG6496 in a randomized, placebo-controlled, investigator/participant-blind study with an open-label extension in Huntington's disease gene expansion carriers (POINT-HD)

GO TO STUDY

Respiratory

A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis. (M25-268)

GO TO STUDY

Inflammatory and immune system

A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA) (CHILL (QEL-005-CLN-01))

GO TO STUDY

Cancer and neoplasms

CA266-0004: A Randomized Phase 2/3 Study of BMS-986545-01 (BNT327) in Combination with Chemotherapy Versus Standard of Care in Previously Untreated Participants with Unresectable, Metastatic, or Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

GO TO STUDY

Cancer and neoplasms

A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC whose tumor PD-L1 status is considered negative (BNT327-05 (ROSETTA-Breast 01))

GO TO STUDY